<DOC>
	<DOCNO>NCT02291770</DOCNO>
	<brief_summary>Chronic Graft-versus-Host Disease ( cGvHD ) potentially lethal disorder . A variety second line immunosuppressive agent investigate optimal treatment emerge . There therefore need novel treatment strategy . Mesenchymal stromal cell ( MSC ) exhibit immunomodulatory property recent pilot study suggest response rate 70 % steroid- refractory patient . In present randomize study efficacy safety MSC treatment study patient cGvHD .</brief_summary>
	<brief_title>Treatment Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Newly diagnose cGvHD Informed consent obtain patient donor . Any patient undergone allogeneic stem cell transplantation c GvHD . Have receive additional agent cGVHD within 3 month . Expected life 90 day . Adequate pulmonary function evidence chronic obstructive severe restrictive pulmonary disease . Adequate cardiac function evidence uncontrolled high blood pressure , congestive heart failure , angina pectoris , acute myocardial infarction within 6 month prior process . Invasive fungal disease . Active cytomegalovirus ( CMV ) /EpsteinBarr virus ( EBV ) /varicella disease ) . Patient history hypersensitivity bovine product . Relapsed malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Chronic Graft-Versus-Host Disease</keyword>
	<keyword>Mesenchymal Stromal Cells</keyword>
</DOC>